Rescuing drug discovery: in vivo systems pathology and systems pharmacology
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 4 (12) , 961-967
- https://doi.org/10.1038/nrd1904
Abstract
The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been brought into question. Here, we discuss whether taking an in vivo systems approach to drug discovery and development could be the paradigm shift that rescues the industry.Keywords
This publication has 29 references indexed in Scilit:
- Can cell systems biology rescue drug discovery?Nature Reviews Drug Discovery, 2005
- Cell Fates as High-Dimensional Attractor States of a Complex Gene Regulatory NetworkPhysical Review Letters, 2005
- Metabolic Syndrome and Robustness TradeoffsDiabetes, 2004
- The myth of the biotech revolutionTrends in Biotechnology, 2004
- Primer on Medical Genomics Part XIV: Introduction to Systems Biology—A New Approach to Understanding Disease and TreatmentMayo Clinic Proceedings, 2004
- Prospects for productivityNature Reviews Drug Discovery, 2004
- Are the Economics of Pharmaceutical Research and Development Changing?PharmacoEconomics, 2004
- Life's Complexity PyramidScience, 2002
- A NEWAPPROACH TODECODINGLIFE: Systems BiologyAnnual Review of Genomics and Human Genetics, 2001
- Pyrolysis-direct chemical ionization mass spectrometry of the dimorphic fungus Candida albicans and the pleomorphic fungus Ophiostoma ulmiJournal of Analytical and Applied Pyrolysis, 1989